CTOs on the Move

Locus Pharmaceuticals

www.locuspharma.com

 
Locus Pharmaceuticals, Inc. is a world leader in fragment-based, computational drug design. We have combined highly integrated chemistry, crystallography and biology capabilities to create a unique drug design and development platform for oral drug
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

Tweed

Tweed and our sister company Tweed Farms are wholly owned subsidiaries of Tweed Marijuana Inc., traded on the TSX Venture Exchange as TWD. We are a Canadian company licensed under the Marihuana for Medical Purposes Regulations. We strive to supply a wide selection of marijuana, as diverse as the patients who trust us with their patronage.

Vishnu Chemicals Limited

Vishnu Chemicals Limited is a Eatontown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Century INfusion Solutions

New Century INfusion Solutions is a Brea, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deciphera

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.